187 results on '"Hoogendoorn, Mels"'
Search Results
2. New treatment opportunities for older patients with acute myeloid leukemia and the increasing importance of frailty assessment – An oncogeriatric perspective
3. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
4. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL
5. Treatment patterns in older patients with myelodysplastic syndromes: A population-based analysis reflecting the real world
6. Effectiveness of a vitamin D regimen in deficient multiple myeloma patients and its effect on peripheral neuropathy
7. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial
8. Improving the identification of frail elderly newly diagnosed multiple myeloma patients
9. Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features
10. Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study
11. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
12. Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study
13. No decrease in fracture risk despite 15 years of treatment evolution for multiple myeloma patients: A Danish nationwide case-control study
14. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment
15. Validation of the EUTOS long-term survival score in a recent independent cohort of “real world” CML patients
16. No outcome disparities in patients with diffuse large B-cell lymphoma and a low socioeconomic status
17. Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion
18. New insights in the neurological phenotype of aceruloplasminemia in Caucasian patients
19. Native aortic valve endocarditis with Morganella morganii in a patient with multiple myeloma and valvular amyloidosis: a case report
20. BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population.
21. MYC expression and translocation analyses in low‐grade and transformed follicular lymphoma
22. Validation of and proposals for refinements of the WHO 2016 classification for myelodysplastic syndromes
23. Influence of WHO versus ELN advanced phase chronic myeloid leukemia definitions on overall survival
24. Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)
25. Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands.
26. The GLOW trial in chronic lymphocytic leukaemia
27. Clinical view versus guideline adherence in ferritin monitoring and initiating iron chelation therapy in patients with myelodysplastic syndromes.
28. Management of infection prophylaxis in Dutch patients with myelodysplastic syndromes, a web‐based case vignette questionnaire: The MINDSET study.
29. Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients
30. Serial ADAMTS13 measurements during initial plasma exchange therapy guide decisions for management of unresponsive thrombotic thrombocytopenic purpura
31. Paediatric nodal marginal zone B-cell lymphadenopathy of the neck: a Haemophilus influenzae-driven immune disorder?
32. Increased prescription rate of anti‐infective agents after diagnosis of myelodysplastic syndromes.
33. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study
34. A clinical effect of disease-modifying treatment on alloimmunisation in transfused patients with myelodysplastic syndromes: data from a population-based study.
35. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme
36. Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view.
37. Patterns of transfusion burden in an unselected population of patients with myelodysplastic syndromes: A population‐based study.
38. Kinase Domain Mutation Testing and Clinical Outcome in a Nationwide Chronic Myeloid Leukemia Patient Population
39. Do not give paraffin to packers
40. Implications of chills
41. Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84).
42. Bortezomib maintenance after R‐CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
43. Rituximab‐PECC induction followed by 90Y‐ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study.
44. No Decrease in Fracture Risk Despite 15 Years of Treatment Evolution in Multiple Myeloma Patients: A Danish Nationwide Case-Control Study
45. Peripheral Neuropathy and Hypovitaminosis D Are Associated in Multiple Myeloma Patients
46. Role of Disease Modifying Treatment in the Risk of Alloimmunization in Transfused Patients with Myelodysplastic Syndromes: A Population-Based Study
47. Relapse in stage I(E) diffuse large B-cell lymphoma.
48. Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe.
49. Restoration of renal function in patients with newly diagnosed multiple myeloma is not associated with improved survival: a population-based study.
50. Fatal Cobalt Toxicity after a Non-Metal-on-Metal Total Hip Arthroplasty.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.